Ras-MAPK pathway as a therapeutic target in cancer - Emphasis on bladder cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 2, 2009, Pages 125-136

  Dangle, Pankaj P ^a   Zaharieva, Boriana ^a   Jia, Hongtao ^a   Pohar, Kamal S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bladder cancer; New potential therapeutic targets; Ras MAPK pathway

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GREEN TEA EXTRACT; IMATINIB; LAPATINIB; LONAFARNIB; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROHIBITIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SORAFENIB; SUNITINIB; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; VATALANIB; ANTINEOPLASTIC AGENT; FARNESYL TRANS TRANSFERASE; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; CELL KILLING; CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC REGULATION; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BLADDER TUMOR; DRUG ANTAGONISM; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; FARNESYLTRANSTRANSFERASE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 68949103943     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209788452812     Document Type: Review

References (100)

1. Bhise SB, Nalawade AD, Wadhawa H. Role of protein tyrosine kinase inhibitors in cancer therapeutics. Ind J Biochem Biophys 2004; 41: 273-280.
2. Flanagan JG, Vanderhaeghen P. The ephrins and Eph receptors in neural development. Annu Rev Neurosci 1998; 21: 309-345.
3. Holland SJ, Peles E, Pawson T, Schlessinger J. Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase beta. Curr Opin Neurobiol 1998; 8: 117-127.
4. Kuriyan J, Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu Res Biophys Biomol Struct 1997; 26: 259-288.
5. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69: 373-398.
6. Rodrigues GA, Park M. Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 1994; 4: 15-24.
7. Hunter T. Oncoprotein networks. Cell 1997; 88; 333-346.
8. Biscardi JS, Tice DA, Parsons SJ. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 1999; 76: 61-119.
9. Lemmon MA, Ferguson KM. Pleckstrin homology domains. Curr Top Microbiol Immunol 1998; 228: 39-74.
10. Tonks NK, Neel BG. From form to function: Signaling by protein tyrosine phosphatases. Cell 1996; 87: 365-68.
11. Downward J. Ras signaling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54.
12. Gille H, Downward J. Multiple ras effectors pathways contribute to G(1) progression. J Biol Chem 1999; 274: 22033-22040.
13. Hodgkin MN, Pettitt TR, Martin A, et al. Diacylglycerols and phosphatidates: Which molecular species are intracellular messengers? Trends Biochem Sci 1998; 23: 200-204.
14. Kresse H, Schonherr E. Proteoglycans of the extracellualr matrix in growthcontrol. J Cell Physiol 2001; 189: 266-274.
15. Oxford G, Theodorescu D. The role of RAS superfamily proteins in bladder cancer progression. J Urol 2003; 170: 1987-1993.
16. Barbacid M. Ras genes. Annu Rev Biochem 1987; 56: 779-827.
17. Bos J. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-4689.
18. Rodriguez-Viciana P, Tetsu O, Oda K, et al. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 2005; 70: 461-467
19. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000; 100: 57-70.
20. www.cancer.gov-nci. Statistics, Bladder cancer.
21. Rieger-Christ KM, Mourtzinos A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003; 98: 737-744.
22. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004; 64: 1911-1914.
23. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 8108-8112.
24. Knowles MA, Williamson M. Muation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphism, and direct sequencing. Cancer Res 1993: 53: 133-139.
25. Saito S, Hata M, Fukuyama R, et al. Screening of H-ras gene point mutation in 50 cases of bladder carcinoma. Int J Urol 1997; 4: 178-185.
26. Cerutti P, Hussain P, Pourzand C, Aguilar F. Mutagensis of the Hras protooncogene and the p53 tumor suppressor gene. Cancer Res 1994; 54: 1934-1938.
27. Burchill SA, Neal DE, Lunec J. Frequency of H-ras mutations in human bladder cancer detected by dorect sequencing. Br J Urol 1994; 73: 516-521.
28. Olderoy G, Daehlin L, Ogreid D. Low-frequency mutation of Haras and Ki-ras oncogenes in transitional cell carcinoma of the bladder. Anticancer Res 1998: 18: 2675-2678.
29. Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and NRAS gene activation in human bladder cancers. Cancer Genet Cytogenet 2000: 121: 73-77.
30. Vageli D, Kiaris H, Delakas D, et al. Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors. Cancer Lett 1996; 107: 241-247.
31. von Lintig FC, Dreilinger AD, Varki NM, et al. Ras activation in human breast cancer. Breast Cancer Res Treat 2000; 62: 51-62.
32. von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR. Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin Cancer Res 2000; 6: 1804-1810.
33. Aaltonen V, Bostrom PJ, Soderstrom KO, et al. Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. Am J Pathol 1999; 154: 755-765.
34. Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001; 61: 6688-6692.
35. Li M, Gu FL, Li WB, et al. Introduction of wild-type p53 gene downregulates the expression of H-ras gene and suppresses the growth of bladder cancer cells. Urol Res 1995; 23: 311-314.
36. Lin JH, Zhao H, Sun TT. A tissue-specific promoter that can drive a foreign gene to express in the suprabasal urothelial cells of transgenic mice. Proc Natl Acad Sci USA 1995; 92: 679-683.
37. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20: 1973-1980.
38. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002; 62: 4157-4163.
39. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999; 59: 3512-3517.
40. Khosravi-Far R, White MA, Westwick JK, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 1996; 16: 3923-3933.
41. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
42. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/ RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934-937.
43. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-6455.
44. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
45. Simon R, Richter J, Wagner U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001; 61: 4514-4519.
46. Wong AS, Kim SO, Leung PC, Auersperg N, Pelech SL. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 2001; 82: 305-311.
47. Downes CP, Bennett D, McConnachie G, et al. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 2001; 29: 846-851.
48. Liu J, Babaian DC, Liebert M, Steck PA, Kagan J. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol Carcinog 2000; 29: 143-150.
49. Wang DS, Rieger-Christ K, Latini JM, et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 2000; 88: 620-625.
50. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressoronco-protein network. Trends Biochem Sci 2002; 27: 462-467.
51. Freeman DJ, Li AG, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase dependent and -independent mechanisms. Cancer Cell 2003; 3: 117-130.
52. Theodorescu D, Laderoute KR, Gulding KM. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Diff 1998; 9: 919-928.
53. Herbsleb M, Christensen OF, Thykjaer T, et al. Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situ in the urinary bladder. BMC Cancer 2008; 8: 37.
54. Diaz De Stahl, Segersten U, Malmstrom PU. Molecular gnetics of bladder cancer:an update. Minerva Urol Nefrol 2008; 60(40): 205-216
55. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
56. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by ckit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145.
57. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-5797.
58. Anonymous. Dasatinib (Sprycel) for CML and Ph + ALL. Med Lett Drugs Ther 2007; 49: 6-7.
59. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10: 136-143.
60. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
61. Frederick BA, Helfrich BA, Coldren CD, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007; 6: 1683-1691.
62. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-7670.
63. Nelson MH, Dolder CR. Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006; 40: 261-269.
64. Gomez HL, Chavez MA, Doval DC, et al. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat 2005; 94: Abstract 1071.
65. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6: 2356-2362.
66. Tuma RS. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. J Natl Cancer Inst 2007; 99: 348-349.
67. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
68. McKeage K, Wagstaff AJ. Sorafenib: In advanced renal cancer. Drugs 2007; 67: 475-484.
69. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4(12): 937-947.
70. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
71. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 2005; 23(23): 5386-5403.
72. Crooke ST. Potential roles of antisense technology in cancer treatment chemotherapy. Oncogenes 2000; 19: 6651-6659.
73. Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51: 1744-1748.
74. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874-4884.
75. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. Clin Oncol 2007; 25(16): 2218-2224
76. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007; 6(1): 277-285.
77. Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24: 1892-1897.
78. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59(2): 183-195.
79. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006; 12: 144-151.
80. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005; 5: 188-196.
81. Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase independent apoptosis in melanoma cells. Cancer Res 2006; 66: 1611-1619.
82. Gallagher DJ, Milowsky MI, Gerst SR, et al. Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). J Clin Oncol 2008; 26: 5082.
83. Wülfing C, Machiels J, Richel D, et al. A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. ASCO Annual Meeting Proceedings, 23, 16S, Part I of II, J Clin Oncol 2005; 4594.
84. Winquist E, Moore MJ, Chi KN, et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 2005; 23(3): 143-149.
85. Wang KJ, Wang RT, Zhang JZ. Identification of tumor markers using two-dimensional electrophoresis in gastric carcinoma. World J Gastroenterol 2004; 10: 2179-2183.
86. Srisomsap C, Subhasitanont P, Otto A, et al. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2002; 2: 706-712.
87. Teck KS, Shao-En O, Rosa CMYL, et al. Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry. Electrophoresis 2000; 21: 1787-1813.
88. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003; 94: 575-581.
89. Rajalingam, K., Rudel, T.: WO2006032528A1 (2006).
90. Mukherjee, A., Tang, M., Pannu H.S., Chan-hui, P.-Y., Singh S.: US20050131006 (2005).
91. Blenis, J., Murphy, L. O.: WO2005007090 (2005).
92. Kolesnick, R. N., Xing, H. R.: US20050037455 (2005).
93. Kolesnick, R. N., Xing, H. R.: US200896840 (2008).
94. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93: 1062-1074.
95. Hamilton M. Wolfman A. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor. J Biol Chem 1998; 273: 28155-28162.
96. Xing HR, Kolesnick R. Kinase suppressor of Ras signals through Thr269 of c-Raf-1. J Biol Chem 2001; 276: 9733-9741.
97. Gahman, T.C., Lang, H., Davis, R.L., Scranton, S.A.: WO2006124874A2 ( 2006).
98. Bold, G., Brueggen, J.B., Huang, J.M.-J., Kinder, Jr. F.R., Lane H., Latour, E.J., Chaussée, F., Manley, P.W., Wood, J.M.: WO2005027972A2 (2005).
99. Dent, P., Grant, S., Mckinstry, R., Dai, Y., Yu, C.: US20040191168 ( 2004).
100. Slack, F.J., Johnson, S.M., Grosshans, H.: US20080119436 (2008).